Abstract

It has just been determined that cancer is the primary cause of death globally. Numerous traditional remedies as well as cytotoxic immunotherapies have been created and introduced to the market. A promising immunotherapy that targets tumours at both the cellular and genetic levels is required, given the complicated behaviour of tumours and the involvement of several genetic and cellular components involved in tumorigenesis and metastasis. One innovative therapeutic T cell engineering technique that has gained traction is chimeric antigen receptor (CAR) Chimergic Antigen Receptor - T cell therapy. Studies on CAR-T cell design are still ongoing in response to these problems, with the goal of achieving higher therapeutic efficacy and safety. It is anticipated that CAR-T cell therapy will play a significant role in cancer treatment in the future and could offer novel concepts and approaches for tailored immunotherapy. The current study offers a thorough summary of the fundamentals, therapeutic efficacy, clinical applications, and difficulties associated with CAR-T cell treatment.

Keywords

Introduction

       
           
       
Fig :- Adoptive Car T Cell Therapy

How Do Car T Cells Kills?

       
           
       
Fig :-Schematics of T cell and CAR T cell killing mechanisms

Currently Available Car T Cell Therapies :

       
           
       
 Fig :- Structure Of The Car T Cell

Architectural ideology of T cell engineering and CAR Design :

       
           
       
Fig :- Simplified visualization of the steps involved in an example manufacturing process for  CAR T cells

The manufacturing of CAR T cells is a multi-step, one-to-two-week-long ex vivo process which deeply affects functionality, and thus influences the outcomes of both preclinical results and therapy. Peripheral blood mononuclear cells (PBMCs) are collected and isolated to start the general production process. Leukapheresis is a kind of apheresis that automatically isolates leukocytes. Alternatively, the patient’s blood can be drawn and separated into distinct components (e.g., using density-gradient centrifugation with Ficoll-Paque).This can be accomplished using viral or non-viral methods that introduce the CAR construct into the lymphocytes. The separated T cells must then undergo genetic alteration. This can be accomplished using viral or non-viral methods that introduce the CAR construct into the lymphocytes. The construct is often DNA-encoded, integrating into the T cell genome to provide long-term expression. Additionally, transitory expression is possible with RNA-based designs, which can aid to enhance toxicity profiles. The most common method for producing CAR T cells is viral technique, which often uses costly lentiviral or ?-retroviral vectors with high transduction effectiveness.

• ---

  Conditional Expression of CAR T cells :

Expression with conditions After being exposed to a specific stimulus, CAR T cells only express the normal CAR construct. This stimulus can take the form of a soluble ligand, but it is possible to induce the production of two different CARs in these cells: a “priming” CAR that lacks CD3? and is able to induce the development of a second, “true” CAR. Since this final kind of conditional expression CAR necessitates the presence of two antigens, it is also thought to operate as a specific kind of AND operator. The genuine CAR construct, on the other hand, is induced to express itself when the priming CAR recognises the first antigen. This allows the CAR T cell to be activated upon identification of the second antigen.

1.  Switchable CARs :-

These CARs allow for the replacement of a module, specifically the LBD, as their name would seem to suggest. To do this, a CAR with an ectodomain that attaches to a modified soluble LBD via a tiny ligand is created in place of a conventional LBD. This enables the patient to get alternative LBDs and regulate the concentration of the tiny ligand, hence changing the targeting of the CARs. This tactic is especially helpful since it decreases the occurrence of antigen-escape phenomena by rerouting CAR T cell targeting towards subpopulations of cancer cells that evade the first targeting.

2. Inhibitory CARs :-

iCAR builds function as an add on for the primary CAR. In summary, upon binding to its target, an iCAR triggers inhibitory pathways which obstruct any activation signals originating from the primary CAR. Essentially, when healthy cells co-express the inhibitory antigen an antigen that, ideally, only malignant cells express and the primary CAR's cognate antigen, CAR T cells with iCARs will not be able to activate. Once more, this kind of approach lessens toxicity off-tumor. The idea of iCARs, or CARs containing an inhibitory signalling domain, is to improve the on-tumor specificity of CAR-T cell treatments. CAR/iCAR coexpressing T cells are intended to kill cancer cells but not healthy cells expressing the CAR antigen if the iCAR target antigen is substantially expressed on healthy tissue but is not expressed by cancer cells. We used a well-established reporter cell system in this work to show that iCAR constructs containing signalling domains derived from BTLA have a high efficacy. Subsequently, ?CD19-iCARs were able to inhibit T cell proliferation and cytokine generation in primary human T cells.

3. Suicide CAR T cells :-

Suicide CAR T cells contain an inbuilt “off-switch,” as implied by their name. For instance, they may produce a ligand-inducible caspase, which, upon encountering the ligand, dimerises and activates, thereby instigating the death of T cells. By employing this technique, clinicians can promptly and safely stop an excessive or undesired CAR T cell response by providing the patient with the proper ligand. A dimerisation domain linked to a caspase-9 domain was encoded by the suicide gene. Mice's tumours were eradicated by T cells that expressed the anti-SLAMF7 CAR with suicide-gene construct, which precisely recognised SLAMF7 in vitro. Applying the dimerising chemical AP1903 (rimiducid) on demand destroyed T cells bearing this construct.

CONCLUSION :

Numerous B cell-associated cancers have been successfully treated using CAR-T cell therapy, a ground-breaking immunotherapy. For individuals for whom traditional therapies have not worked, CAR-T cells offer a novel treatment option by identifying and eliminating malignant cells by targeting certain antigens on the surface of tumours. Nevertheless, there are still a lot of obstacles and restrictions with CAR-T cell treatment. During treatment, severe side effects as CRS and neurotoxicity could happen. On the other hand, CAR-T cell efficacy and endurance may be restricted by immune escape mechanisms and tumour microenvironment suppression. Thus, one of the main research focusses is to significantly improve the safety, specificity, and durability of CAR-T cell treatments. It is anticipated that CAR-T cell therapy will continue to advance and be used in the future. First, there will be ongoing improvements made to the design and manufacture of CAR-T cells, including the introduction of genetically modified CAR-T cells, changeable switch systems, and bispecific CARs. Second, a broader spectrum of illnesses, including infectious diseases, autoimmune disorders, and different forms of cancer, may be treated using CAR-T cell therapy. A hinge region, a transmembrane domain, an extracellular target antigen-binding domain, and one or more intracellular signalling domains make up the four primary parts of CARs, which are modular synthetic receptors. The treatment of several haematological cancers has been completely transformed by CAR-T cells. Nevertheless, there are still challenges, which were covered in this assessment. It is difficult to train a workforce to match the demands of this dynamic and complicated profession, and creative curriculum development is needed.6. The function of CAR-T cells depends on antigen selection.Because of the CAR-T cells’ selective pressure, tumour cells have the ability to downregulate antigens. It can be difficult to obtain CAR-T cells to migrate to and infiltrate solid tumours.CAR-T cell therapy has completely changed how solid tumours and a variety of haematological malignancies are treated. This innovative strategy uses genetically engineered T cells’ ability to identify and destroy cancer cells.

CAR-T cell therapy has revolutionized the way hematological malignancies are treated and offers potential for solid tumors. This therapy’s potential to improve patient outcomes will be expanded by ongoing research and innovation, which will also address obstacles.

REFERENCES

1. Restifo NP, Dudley ME and Rosenberg SA: Adoptive immunotherapy for cancer: Harnessing the T cell response. Nat Rev Immunol 12: 269?281, 2012.https://www.spandidos-publications.com/10.3892/or.2019.7335?text=fulltext
2. Galluzzi L and Martin P: CARs on a highway with roadblocks. Oncoimmunology 6: e1388486, 2017.https://pubmed.ncbi.nlm.nih.gov/29209574/
3. Perales MA, Kebriaei P, Kean LS and Sadelain M: Building a Safer and faster CAR: Seatbelts, airbags, and CRISPR. Biol Blood Marrow Transplant 24: 27?31, 2018.
4. Sharpe M and Mount N: Genetically modified T cells in cancer Therapy: Opportunities and challenges. Dis Model Mech 8: 337-350, 2015.
5. McGuirk J, Waller EK, Qayed M, Abhyankar S, Ericson S, Holman P, Keir C and Myers GD: Building blocks for institutional Preparation of CTL019 delivery. Cytotherapy 19: 1015?1024, 2017.
6. Prasad V: Immunotherapy: Tisagenlecleucel?the first approved CAR-T-cell therapy: Implications for payers and policy makers. Nat Rev Clin Oncol 15: 11-12, 2018.
7. Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, Komanduri KV, Lin Y, Jain N, Daver N, et al: Chimeric Antigen receptor T?cell therapy?assessment and management of Toxicities. Nat Rev Clin Oncol 15: 47-62, 2018.
8. Miliotou AN and Papadopoulou LC: CAR T-cell therapy: A new Era in cancer immunotherapy. Curr Pharm Biotechnol 19: 5?18, 2018.
9. Mirzaei HR, Jamali A, Jafarzadeh L, Masoumi E, Alishah K, Fallah Mehrjardi K, Emami SAH, Noorbakhsh F, Till BG and Hadjati J: Construction and functional characterization of a fully Human anti?CD19 chimeric antigen receptor (huCAR)?expressing Primary human T cells. J Cell Physiol 234: 9207?9215, 2019.
10. Vormittag P, Gunn R, Ghorashian S and Veraitch FS: A guide to Manufacturing CAR T cell therapies. Curr Opin Biotechnol 53: 164-181, 2018.https://scholar.google.com/scholar_lookup?title=A guide to manufacturing CAR T cell therapies
11. Abate?Daga D and Davila ML: CAR models: Next?generation CAR modifications for enhanced T-cell function. Mol Ther Oncolytics 3: 16014, 2016.
12. Yang QY, Yang JD and Wang YS: Current strategies to improve The safety of chimeric antigen receptor (CAR) modified T cells. Immunol Lett 190: 201?205, 2017.
13.  Mirzaei HR, Mirzaei H, Namdar A, Rahmati M, Till BG and Hadjati J: Predictive and therapeutic biomarkers in chimeric Antigen receptor T?cell therapy: A clinical perspective. J Cell Physiol 234: 5827?5841, 2019.
14. Dai H, Wang Y, Lu X and Han W: Chimeric antigen receptors Modified T?cells for cancer therapy. J Natl Cancer Inst 108: pii: Djv439, 2016.
15. Mirzaei HR, Mirzaei H, Lee SY, Hadjati J and Till BG: Prospects For chimeric antigen receptor (CAR) ?? T cells: A potential Game changer for adoptive T cell cancer immunotherapy. Cancer Lett 380: 413-423, 20https://scholar.google.com/scholar_lookup?title=Prospects for chimeric antigen receptor (CAR) ?? T cells: A potential game changer for adoptive T cell cancer immunotherapy
16. Tsimberidou AM, Fountzilas E, Nikanjam M and Kurzrock R: Review of precision cancer medicine: Evolution of the treatment paradigm. Cancer Treat Rev 86:102019, 2020
17. Locke, F. L. et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N. Engl. J. Med. 386, 640–654 (2022).Article PubMed CAS Google Scholar
18. Schett, G., Mackensen, A. & Mougiakakos, D. CAR T-cell therapy in autoimmune diseases. Lancet 402, 2034–2044 (2023).
19. Shah, B. D. et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet 398, 491–502 (2021).Article PubMed CAS Google Scholar
20. Locke, F. L. et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 20, 31–42 (2019).Article PubMed CAS Google Scholar
21. Wang, M. et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N. Engl. J. Med. 382, 1331–1342 (2020).
22. Muller, F. et al. CD19 CAR T-cell therapy in autoimmune disease—a case series with follow-up. N. Engl. J. Med. 390, 687–700 (2024).Article PubMed Google Scholar
23. Shimabukuro-Vornhagen, A. et al. Cytokine release syndrome. J. Immunother. Cancer 6, 56 (2018).
24. Karschnia, P. et al. Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells. Blood 133, 2212–2221 (2019).
25. Eshhar Z. The T-body approach: redirecting T cells with antibody specificity. Handb Exp Pharmacologic. 2008;181:329–42.Article CAS Google Scholar
26. Curran KJ, Pegram HJ, Brentjens RJ. Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions. J Gene Med. 2012;14(6):405–15.
27. Dai H, Wang Y, Lu X, Han W. Chimeric antigen receptors modified T-cells for cancer therapy. J Natl Cancer Inst. 2016;108(7):djv439.
28. Eshhar Z, Waks T, Gross G, Schindler DG. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci U S A. 1993;90(2):720–4.
29. Turtle CJ, Hanafi LA, Berger C, Gooley TA, Cherian S, Hudecek M, Sommermeyer D, Melville K, Pender B, Budiarto TM, et al. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J Clin Invest. 2016;126(6):2123–38.Article PubMed PubMed Central Google Scholar
30. Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, Fry TJ, Orentas R, Sabatino M, Shah NN, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet (London, England). 2015;385(9967):517–28.
31. Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, Chew A, Gonzalez VE, Zheng Z, Lacey SF, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16):1507–17.Article CAS PubMed PubMed Central Google Scholar
32. Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K, Chung SS, Stefanski J, Borquez-Ojeda O, Olszewska M, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014;6(224):224ra225.
33. Turtle CJ, Hanafi LA, Berger C, Hudecek M, Pender B, Robinson E, Hawkins R, Chaney C, Cherian S, Chen X, et al. Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells. Sci Transl Med. 2016;8(355):355ra116.
34. Kochenderfer JN, Dudley ME, Kassim SH, Somerville RP, Carpenter RO, Stetler-Stevenson M, Yang JC, Phan GQ, Hughes MS, Sherry RM, et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol. 2015;33(6):540–9.Article CAS PubMed Google Scholar
35. Santomasso, B. D. et al. Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with b-cell acute lymphoblastic leukemia. Cancer Discov. 8, 958–971 (2018).
36. Sterner, R. & Kenderian, S. Myeloid cell and cytokine interactions with chimeric antigen receptor-T-cell therapy: implication for future therapies. Curr.Opin. in Hematol. 27, 41–48 (2020).
37. Neelapu, S. S. et al. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat. Rev. Clin. Oncol. 15, 47–62 (2018).
38. Lee, D. W. et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol. Blood Marrow Transplant. 25, 625–638 (2019).
39. Davila, M. L. et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci. Transl. Med. 6, 224ra25 (2014).
40. Lee, D. W. et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 124, 188–195 (2014). Milone, M. C. & Bhoj, V. G. The pharmacology of T cell therapies. Mol. Ther. Methods Clin. Dev. 8, 210–221 (2018).
41. Ying, Z. et al. A safe and potent anti-CD19 CAR T cell therapy. Nat. Med. 25, 947–953 (2019)
42. Salter, AI. et al. Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function. Sci. Signal 11, 544 (2018)
43. Posey Jr AD, Schwab RD, Boesteanu AC, Steentoft C, Mandel U, Engels B, Stone JD, Madsen TD, Schreiber K, Haines KM, et al. Engineered CAR T cells targeting the cancer-associated Tn-glycoform of the membrane mucin MUC1 control adenocarcinoma. Immunity. 2016;44(6):1444–54.Article CAS PubMed Google Scholar
44. Ma Q, Garber HR, Lu S, He H, Tallis E, Ding X, Sergeeva A, Wood MS, Dotti G, Salvado B, et al. A novel TCR-like CAR with specificity for PR1/HLA-A2 effectively targets myeloid leukemia in vitro when expressed in human adult peripheral blood and cord blood T cells. Cytotherapy. 2016;18(8):985–94.
45. Zhang G, Wang L, Cui H, Wang X, Zhang G, Ma J, Han H, He W, Wang W, Zhao Y, et al. Anti-melanoma activity of T cells redirected with a TCR-like chimeric antigen receptor. Sci Rep. 2014;4:3571.
46. Roybal KT, Rupp LJ, Morsut L, Walker WJ, McNally KA, Park JS, Lim WA. Precision tumor recognition by T cells with combinatorial antigen-sensing circuits. Cell. 2016;164(4):770–9.Article CAS PubMed PubMed Central Google Scholar
47. Blankenstein T. Receptor combinations hone T-cell therapy. Nat Biotechnol. 2016;34(4):389–91.
48. Fedorov VD, Themeli M, Sadelain M. PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses. Sci Transl Med. 2013;5(215):215ra172.Article PubMed PubMed Central Google Scholar
49. Barrett DM, Zhao Y, Liu X, Jiang S, Carpenito C, Kalos M, Carroll RG, June CH, Grupp SA. Treatment of advanced leukemia in mice with mRNA engineered T cells. Hum Gene Ther. 2011;22(12):1575–86.
50. Tanyi JL, Haas AR, Beatty GL, Morgan MA, Stashwick CJ, O’Hara MH, Porter DL, Maus MV, Levine BL, Lacey SF, et al. Abstract CT105: Safety and feasibility of chimeric antigen receptor modified T cells directed against mesothelin (CART-meso) in patients with mesothelin expressing cancers. Cancer Res. 2015;75(15 Supplement):CT105.
51. Juillerat A, Marechal A, Filhol JM, Valton J, Duclert A, Poirot L, Duchateau P. Design of chimeric antigen receptors with integrated controllable transient functions. Sci Rep. 2016;6:18950.
52. Wu CY, Roybal KT, Puchner EM, Onuffer J, Lim WA. Remote control of therapeutic T cells through a small molecule-gated chimeric receptor. Science. 2015;350(6258):aab4077.
53. Kim MS, Ma JS, Yun H, Cao Y, Kim JY, Chi V, Wang D, Woods A, Sherwood L, Caballero D, et al. Redirection of genetically engineered CAR-T cells using bifunctional small molecules. J Am Chem Soc. 2015;137(8):2832–5.Article CAS PubMed Google Scholar
54.  JS, Kim JY, Kazane SA, Choi SH, Yun HY, Kim MS, Rodgers DT, Pugh HM, Singer O, Sun SB, et al. Versatile strategy for controlling the specificity and activity of engineered T cells. Proc Natl Acad Sci U S A. 2016;113(4):E450–8